ACAD ACADIA PHARMACEUTICALS INC

Ownership history in Stonepine Capital Management, LLC  ·  8 quarters on record

AI Ownership Summary

Stonepine Capital Management, LLC reported ACADIA PHARMACEUTICALS INC (ACAD) in 8 quarterly 13F filings from 2024 Q2 through 2025 Q4. Peak portfolio weight reached 4.76% in 2025 Q2. The latest visible filing shows ACAD at 1.95% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this ACAD ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Stonepine Capital Management, LLC's position in ACADIA PHARMACEUTICALS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

ACAD was reported at 1.95% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
4.76% in 2025 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q2 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Stonepine Capital Management, LLC held ACAD — position size vs. price
% of Fund (quarterly)    ACAD price (quarter-end, indexed to 100)
📋 Quarterly Holdings History 7 quarters  
Quarter Action Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 REDUCED 100,000 -74,544 -42.7% 1.95% $2.7M 2026-02-14 (Est.) $22.03
2025 Q3 REDUCED 174,544 -50,456 -22.4% 3.03% $3.72B 2025-11-13 $23.64
2025 Q2 ADDED 225,000 +131,607 +140.9% 4.76% $4.9M 2025-08-13 $25.13
2025 Q1 REDUCED 93,393 -126,607 -57.5% 0.18% $185.8M 2025-05-14 $17.16
2024 Q4 ADDED 220,000 +23,105 +11.7% 3.26% $4.0M 2025-02-14 $20.04
2024 Q3 ADDED 196,895 +191,895 +3837.9% 1.91% $3.0M 2024-11-13 $17.59
2024 Q2 REDUCED 5,000 -189,900 -97.4% 0.07% $81K 2024-08-13 $15.73
1 older quarter hidden  —  Sign in free or upgrade to Premium to see full history

FAQ About Stonepine Capital Management, LLC and ACAD

These are the practical questions this page is built to answer before you even open the full history table.

How long has Stonepine Capital Management, LLC reported owning ACAD?

Stonepine Capital Management, LLC reported ACAD across 7 quarterly 13F filings, from 2024 Q2 through 2025 Q4.

What was the largest reported ACAD position in Stonepine Capital Management, LLC's portfolio?

The largest reported portfolio weight for ACAD was 4.76% in 2025 Q2.

What is the latest reported ACAD position on this page?

The most recent filing on this page is 2025 Q4, when Stonepine Capital Management, LLC reported 100,000 shares, equal to 1.95% of portfolio, with an estimated market value of $2.7M.

What does the chart on this ACAD ownership page compare?

The chart compares Stonepine Capital Management, LLC's quarterly ACAD portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Stonepine Capital Management, LLC Holdings